BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9540059)

  • 1. Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.
    Postma TJ; van Groeningen CJ; Witjes RJ; Weerts JG; Kralendonk JH; Heimans JJ
    J Neurooncol; 1998 May; 38(1):69-75. PubMed ID: 9540059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
    van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B
    Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
    Zander T; Nettekoven W; Kraus JA; Pels H; Ko YD; Vetter H; Klockgether T; Schlegel U
    J Neurol; 2002 Aug; 249(8):1055-7. PubMed ID: 12195453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
    Jakacki RI; Jamison C; Mathews VP; Heilman DK; Dropcho E; Cornetta K; Macdonald DR; Williams DA
    Med Pediatr Oncol; 1998 Dec; 31(6):483-90. PubMed ID: 9835900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
    Bouffet E; Mornex F; Jouvet A; Thiesse P; Mertens P; Helfre S; Sindou M; Bret P
    Bull Cancer; 1997 Oct; 84(10):951-6. PubMed ID: 9435796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.
    Cairncross G; Macdonald D; Ludwin S; Lee D; Cascino T; Buckner J; Fulton D; Dropcho E; Stewart D; Schold C
    J Clin Oncol; 1994 Oct; 12(10):2013-21. PubMed ID: 7931469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.
    Streffer J; Schabet M; Bamberg M; Grote EH; Meyermann R; Voigt K; Dichgans J; Weller M
    J Neurol; 2000 Apr; 247(4):297-302. PubMed ID: 10836623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial chemotherapy in gliomatosis cerebri.
    Sanson M; Cartalat-Carel S; Taillibert S; Napolitano M; Djafari L; Cougnard J; Gervais H; Laigle F; Carpentier A; Mokhtari K; Taillandier L; Chinot O; Duffau H; Honnorat J; Hoang-Xuan K; Delattre JY;
    Neurology; 2004 Jul; 63(2):270-5. PubMed ID: 15277619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
    Webre C; Shonka N; Smith L; Liu D; De Groot J
    Anticancer Res; 2015 Oct; 35(10):5467-72. PubMed ID: 26408710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
    Keogh RJ; Aslam R; Hennessy MA; Coyne Z; Hennessy BT; Breathnach OS; Grogan L; Morris PG
    BMC Cancer; 2021 Feb; 21(1):140. PubMed ID: 33557783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
    van den Bent MJ; Kros JM; Heimans JJ; Pronk LC; van Groeningen CJ; Krouwer HG; Taphoorn MJ; Zonnenberg BA; Tijssen CC; Twijnstra A; Punt CJ; Boogerd W
    Neurology; 1998 Oct; 51(4):1140-5. PubMed ID: 9781544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive oligodendroglioma: a chemosensitive tumor.
    Cairncross JG; Macdonald DR; Ramsay DA
    Neurosurgery; 1992 Jul; 31(1):78-82. PubMed ID: 1641113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas.
    Soffietti R; Rudà R; Bradac GB; Schiffer D
    Neurosurgery; 1998 Nov; 43(5):1066-73. PubMed ID: 9802850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
    Jeremic B; Jovanovic D; Djuric LJ; Jevremovic S; Mijatovic LJ
    J Chemother; 1992 Apr; 4(2):123-6. PubMed ID: 1321239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendroglial Tumors Treated with the PCV Regimen.
    Tabouret E; Reyes-Botero G; Dehais C; Daros M; Barrie M; Matta M; Petrirena G; Autran D; Duran A; Bequet C; Delattre JY; Chinot O
    Anticancer Res; 2015 May; 35(5):2901-8. PubMed ID: 25964574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
    Cai Y; Jiang YG; Wang M; Jiang ZH; Tan ZG
    Medicine (Baltimore); 2020 Sep; 99(38):e22238. PubMed ID: 32957367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.
    Galanis E; Buckner JC; Burch PA; Schaefer PL; Dinapoli RP; Novotny PJ; Scheithauer BW; Rowland KM; Vukov AM; Mailliard JA; Morton RF
    J Clin Oncol; 1998 Sep; 16(9):2953-8. PubMed ID: 9738563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
    Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.